Get started
HANMIPHARMHH

HANMIPHARM

234,000KRWD
−3,500−1.47%
At close at Mar 28, 07:45 GMT
KRW
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Forecast Seasonals

128940 fundamentals

Key facts

Market capitalization‪2.98 T‬KRW
Dividend yield (indicated)0.53%
Price to earnings Ratio (TTM)23.85
Basic EPS (TTM)9,958.28KRW
Founded1973
Employees (FY)—
CEOJong-Yoon Lim
Websitehanmipharm.com
About

Hanmi Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include medicines for high blood pressure, hyperlipidemia, reflux esophagitis, and cerebrovascular disease. The company was founded by Lim Sung-Gi on June 15, 1973 and is headquartered in Hwaseong-si, South Korea.

Ownership
‪‪12.68 M‬‬
Closely held shares
‪‪6.54 M‬‬ (51.61%)
Free Float shares
‪‪6.14 M‬‬ (48.39%)
Closely held shares
‪‪6.54 M‬‬ (51.61%)
Free Float shares
‪‪6.14 M‬‬ (48.39%)
Capital structure
Market cap
‪‪2.98 T‬‬
Debt
‪‪496.69 B‬‬
Minority interest
‪‪155.86 B‬‬
Cash & equivalents
‪‪192.39 B‬‬
Enterprise value
‪‪3.44 T‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪2.98 T‬‬
Price to earning ratio (P/E)
23.85x
Price to sales ratio (P/S)
2.01x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
23.85x
Price to sales ratio (P/S)
2.01x
Valuation ratios
‪0.00‬
‪0.80‬
‪1.60‬
‪2.40‬
‪3.20‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪8.00‬
‪16.00‬
‪24.00‬
‪32.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪0%‬
‪4%‬
‪8%‬
‪12%‬
‪16%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪110.00 B‬‬
‪‪220.00 B‬‬
‪‪330.00 B‬‬
‪‪440.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪90.00 B‬‬
‪‪180.00 B‬‬
‪‪270.00 B‬‬
‪‪360.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪90.00 B‬‬
‪‪180.00 B‬‬
‪‪270.00 B‬‬
‪‪360.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Pharmaceutical Raw Materials
Overseas Pharmaceutical Products
Pharmaceutical Products
By country
Period: 2024
South Korea
China
Other
Japan
United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪110.00 B‬‬
‪‪220.00 B‬‬
‪‪330.00 B‬‬
‪‪440.00 B‬‬
Actual
Estimate
Earnings
Next:Feb 5, 2026
2021
2022
2023
2024
2025
‪0.00‬
‪‪3.50 K‬‬
‪‪7.00 K‬‬
‪‪10.50 K‬‬
‪‪14.00 K‬‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
12.55%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.53%
Last payment
1,000.00
Last ex-date
Dec 27, 2024
Dividend history
‪0.1%‬
‪0.2%‬
‪0.3%‬
‪0.4%‬
‪0.5%‬
2020
2021
2022
2023
2024
‪0.00‬
‪350.00‬
‪700.00‬
‪‪1.05 K‬‬
‪‪1.40 K‬‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪150.00 B‬‬
‪‪300.00 B‬‬
‪‪450.00 B‬‬
‪‪600.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪350.00 B‬‬
‪‪700.00 B‬‬
‪‪1.05 T‬‬
‪‪1.40 T‬‬
Assets
Liabilities